Hudson Bay Capital Management Reduces ACADIA Pharmaceuticals Stake

Hedge fund cuts holdings in biopharmaceutical company by 63%

Mar. 23, 2026 at 8:33am

Got story updates? Submit your updates here. ›

Hudson Bay Capital Management LP has reduced its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 63%, selling 119,700 shares in the third quarter. The hedge fund now owns 70,300 shares of the biopharmaceutical company's stock, worth approximately $1.5 million as of its most recent SEC filing.

Why it matters

ACADIA Pharmaceuticals is a prominent biopharmaceutical company focused on developing treatments for central nervous system disorders. Hudson Bay Capital Management's decision to significantly reduce its position in the company could signal a shift in investor sentiment or a reallocation of the hedge fund's portfolio.

The details

According to the SEC filing, Hudson Bay Capital Management sold 119,700 shares of ACADIA Pharmaceuticals during the third quarter, reducing its total holdings to 70,300 shares. The hedge fund's stake in the biopharmaceutical company is now valued at $1.5 million, down from $4.1 million at the end of the previous quarter.

  • Hudson Bay Capital Management filed the 13F report detailing the stake reduction on March 23, 2026.

The players

Hudson Bay Capital Management LP

A hedge fund that has reduced its stake in ACADIA Pharmaceuticals by 63%.

ACADIA Pharmaceuticals Inc.

A biopharmaceutical company focused on developing treatments for central nervous system disorders.

Got photos? Submit your photos here. ›

The takeaway

The significant reduction in Hudson Bay Capital Management's position in ACADIA Pharmaceuticals could signal a broader shift in investor sentiment towards the biopharmaceutical company. However, it's important to note that this is just one hedge fund's decision and does not necessarily reflect the overall market's view on ACADIA Pharmaceuticals.